STAAR Surgical Names Andrew Pilon as Vice President of Business Development

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the appointment of Andrew Pilon, O.D. as Vice President of Business Development. Dr. Pilon will report to STAAR President and Chief Executive Officer Warren Foust and will work closely with the Company's senior leadership team to capitalize on opportunities th.

Business Wire • Oct 8, 2026

Why Staar Surgical Zoomed Almost 8% Higher on Tuesday

That pundit now believes it's a buy. He cited positive sales momentum, especially in a key market overseas.

The Motley Fool • Sep 29, 2026

This Staar Surgical Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Benzinga • Sep 29, 2026

Why Staar Surgical Stock Soared Today

It anticipates this will run for one year. The company's recent fundamentals have been rather impressive.

The Motley Fool • Sep 25, 2026

STAAR Surgical Board Approves $50 Million Share Repurchase Authorization

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of Directors, at a regularly scheduled meeting, authorized a share repurchase program under which the Company may repurchase up to $50 million of its outstanding common stock. Under its buyback program, STAAR may repurchase shares in the open market, through privately ne.

Business Wire • Sep 24, 2026

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of STAAR Surgical Company (NASDAQ: STAA).

NEW YORK, Sept. 23, 2026 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of STAAR Surgical Company (NASDAQ: STAA) concerning possible breaches of fiduciary duties.

PRNewsWire • Sep 23, 2026

STAAR Surgical Releases Landmark Global Report Showing Structural Multi-Market Shift Toward Lens-Based Vision Correction

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today released a new report entitled The Future of Refractive Surgery, the first comprehensive global market analysis showing a consistent, multi-market migration toward implantable lens correction driven by durable tailwinds on the demand and clinical sides of the market. The report examines patient.

Business Wire • Sep 10, 2026

STAAR Surgical Names Former CEO David Bailey as Chief Commercial Officer

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the appointment of David Bailey as Chief Commercial Officer. Mr. Bailey will join STAAR's executive committee and report to Warren Foust, President and Chief Executive Officer. "David Bailey doesn't just know STAAR, he helped change the trajectory of the entir.

Business Wire • Sep 8, 2026

STAAR Surgical Names Medtech Innovator and Platform Builder Ben Park as Chief Technology Officer

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the appointment of Ben Park, Ph.D., as Chief Technology Officer. Dr. Park will join STAAR's Executive Committee and report to Warren Foust, President and Chief Executive Officer. "Evolving STAAR from a single-product focus into a multi-product platform is cent.

Business Wire • Sep 2, 2026

Deciphering Staar Surgical (STAA) International Revenue Trends

Review Staar Surgical's (STAA) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

Zacks Investment Research • Aug 17, 2026